What is your current approach to maintenance therapy in FLT3-mutant AML post allogeneic HCT?

Have you changed your practice given BMT-CTN 1506/Morpho results?

Would you utilize maintenance therapy in patients who achieve MRD- remission?

Answer from: Medical Oncologist at Academic Institution

I would offer maintenance with FLT3 inhibitor with gilteritinib (NCT02997202: MORPHO trial, not yet published), sorafenib (SORMAIN trial), or midostaurin (RADIUS trial), whichever agent is available. In my experience, gilteritinib appears to be the most tolerable. I suggest beginning maintenance as ...

Comments

Medical Oncologist at West Penn Hospital
Hello Dr. @Yared - I just wanted to clarify ...

Please select the option that best describes you:

What is your current approach to maintenance therapy in FLT3-mutant AML post allogeneic HCT?

Related Questions